Buy Eris Lifesciences; target of Rs 780: Motilal Oswal
Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 780 in its research report dated January 18, 2023.18-01-2023
18-01-2023
Eris Lifesciences Ltd - 540596 - AUDIO RECORDING OF THE EARNINGS CONFERENCE CALL ON THE UNAUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2022
Dear Sir/Madam, In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, we hereby inform you that the Audio Recording of the Earnings Conference Call in connection with the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and nine months ended 31st December 2022, held on Tuesday, 17 January 2023, is available on the website of the Company and can be accessed through the following link: Link: https://eris.co.in/financials/ (File name: Q3 FY23-Earnings Call Recording) Thanking You,17-01-2023
Eris Lifesciences Ltd - 540596 - INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015
Dear Sir/Madam, We would like to inform that the Company has given a corporate guarantee in favour of Eris Oaknet Healthcare Private Limited ('EOHPL'), a Wholly Owned Subsidiary, for securing the Credit facility(ies) that it availed from Citi Bank N.A. Further, in accordance requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B (11) of Part A to the Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, details attached herewith may please be taken on record. The details of the same will also be uploaded on the website of the Company. Thanking You,17-01-2023
Results Earnings Call for Q3FY23 of Eris Lifesciences
Conference Call with Eris Lifesciences Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.17-01-2023
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Acquisition
Dear Sir/Madam, In accordance with the requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A (1) of Part A of Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, details attached herein may be taken on record The details of the same will be uploaded on the website of the Company.17-01-2023
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation
INVESTOR PRESENTATION17-01-2023
Eris Lifesciences Ltd - 540596 - OUTCOME OF THE BOARD MEETING HELD TODAY, I.E., JANUARY 17, 2023
Dear Sir/Madam, The Board of Directors of the Company at their meeting held today, i.e., January 17, 2023 duly approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022. Please find enclosed standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2022. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 05:20 P.M. This is for your information and record. Thanking You,17-01-2023
Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD TODAY, I.E., JANUARY 17, 2023
Dear Sir/Madam, The Board of Directors of the Company at their meeting held today, i.e., January 17, 2023 duly approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022. Please find enclosed standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2022. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 05:20 P.M. This is for your information and record. Thanking You,17-01-2023
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)14-01-2023
Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Dear Sir/Madam, We are enclosing herewith a Confirmation Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended 31 December 2022, received from M/s. Link lntime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company, which is self-explanatory. We duly confirm and certify the same This is for your information and records.13-01-2023